FDA designates another Alexion drug a 'breakthrough'
This article was originally published in Scrip
Executive Summary
Shares of Alexion Pharmaceuticals rose as much as 6.7% on 24 October on news the FDA deemed the company's synthetic form of cyclic pyranopterin monophosphate (cPMP), known as ALXN1101, a breakthrough therapy – the second product in the firm's pipeline to win the status.
You may also be interested in...
BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A
Although small patient base offers modest revenue opportunity, the Nulibry approval enables BridgeBio to get commercial operations underway.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.